Elan Wins $55M From Abraxis In Cancer Drug Suit

Law360, New York (June 16, 2008, 12:00 AM EDT) -- Abraxis BioScience Inc. has vowed to challenge a jury verdict that awarded $55.2 million to plaintiff Elan Pharma International Ltd. and held that Abraxis' breast cancer drug Abraxane infringed on a patent held by Elan.

The verdict was issued Friday in the U.S. District Court for the District of Delaware, where Irish drugmaker Elan sued Los Angeles-based Abraxis in July 2006, claiming infringement of U.S. Patent Numbers 5,399,363 and 5,834,025.

The jury found that Abraxis infringed the '363 patent, which is valid through 2011, according to...
To view the full article, register now.